Thus, VISTA expression on T cells plays a critical role in predicting the clinical manifestations and prognoses of patients with MM and emphasizes a superior role of VISTA inhibitors in the development of systemic immune suppression and myeloma progression. This evidence concerns the gene VSIR and Miyoshi myopathy.